Adherium develops, manufactures and supplies digital health technologies that address suboptimal medicine use in chronic disease.

The Company's first product range is the Smartinhaler™ platform, comprising a range of approved medical devices that attach to prescription inhalers to monitor inhaler actuation and provide audio and visual medication reminders, and the SmartinhalerLive™ software, which integrates the data from the Smartinhalers into a usable form via communications protocols, mobile applications and cloud based software.

It is anticipated that ADR will list on the ASX during August 2015.